Skip to content

US · ELDN · BIOTECHNOLOGY

Eledon Pharmaceuticals, Inc. (ELDN) intrinsic value and stock valuation

$1.78as of 2026-11-21 · Mkt cap 284.82M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Eledon Pharmaceuticals, Inc. DCF and intrinsic value

InvestorsCraft values ELDN with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ELDN’s statements →

Eledon Pharmaceuticals, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Irvine, CA 92612 eledon.com

How the business is doing

Fiscal 2012–2025, USD

Revenue
$0.00
20122025
Net income
-$-45.62M
20122025
Free cash flow
-$-62.34M
20122025
Total equity
$81.1M-15.7% 5y CAGRd
20122025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2012–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-83.25M-$-70.58M-$-43M-$-88.43M-$-36.87M
Net income-$-45.62M-$-36.18M-$-116.54M-$-87.97M-$-34.51M
EPSd-$-557.43K-$-745.36K-$-4.73M-$-6.16M-$-2.33M
Operating cash flow-$-62.34M-$-47.27M-$-39.53M-$-28.42M-$-28.91M
Capital expenditure$0.00$0.00$0.00$0.00$0.00
Free cash flow-$-62.34M-$-47.27M-$-39.53M-$-28.42M-$-28.91M
Total assets$169M$177.4M$89.1M$92.8M$170.6M
Total debt$640K$950K$380K$750K$770K
Net debt-$-22.17M-$-19.59M-$-4.23M-$-55.66M-$-84.06M
Total equity$81.1M$118.1M$7.21M$84.2M$164M
Cash and short-term investments$133.3M$140.2M$51.1M$56.4M$84.8M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00$0.00
Research and development expenses$66.3M$52M$30.3M$27.1M$23.7M
Selling, general and administrative expenses$17M$18.6M$12.7M$12.7M$13.1M
Other expenses$0.00$0.00$0.00$48.7M$0.00
Operating expenses$83.3M$70.6M$43M$88.4M$36.9M
Cost and expenses$83.3M$70.6M$43M$88.4M$36.9M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$310K$360K$370K$370K$200K
Ebitda-$-45.27M-$-35.39M-$-116.16M-$-39.41M-$-36.66M
Operating income-$-83.25M-$-70.58M-$-43M-$-88.43M-$-36.87M
Total other income/expenses, net$37.7M$34.8M-$-73.54M$460K$10K
Income before tax-$-45.58M-$-35.75M-$-116.54M-$-87.97M-$-36.86M
Income tax expense$40K$430K$0.00$0.00-$-2.35M
Net income-$-45.62M-$-36.18M-$-116.54M-$-87.97M-$-34.51M
Weighted average shares outstanding$81.8M$48.5M$24.6M$14.3M$14.8M
Weighted average diluted shares outstanding$81.8M$48.5M$24.6M$14.3M$14.8M
Balance sheet
20252024202320222021
Cash and short-term investments$133.3M$140.2M$51.1M$56.4M$84.8M
Net receivables$510K$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$135.7M$143.7M$56.1M$59.5M$88.4M
Property, plant and equipment, net$610K$930K$360K$740K$770K
Goodwill and intangible assets$32.4M$32.4M$32.4M$32.4M$81M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$33.3M$33.7M$32.9M$33.3M$82.2M
Total assets$169M$177.4M$89.1M$92.8M$170.6M
Accounts payable$3.63M$5.83M$970K$2.2M$1.81M
Short-term debt$360K$310K$380K$360K$370K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$18.3M$11.6M$3.9M$6.47M$4.4M
Long-term debt$280K$640K$0.00$380K$400K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$69.6M$47.7M$78M$2.13M$2.15M
Capital lease obligations$640K$950K$380K$750K$770K
Total liabilities$87.9M$59.3M$81.9M$8.61M$6.55M
Common stock$70K$60K$20K$10K$10K
Retained earnings-$-401.2M-$-355.59M-$-319.4M-$-202.87M-$-114.9M
Accumulated other comprehensive income (loss)$20K$30K$0.00$0.00$0.00
Total equity$81.1M$118.1M$7.21M$84.2M$164M
Total investments$110.5M$119.6M$46.5M$0.00$0.00
Total debt$640K$950K$380K$750K$770K
Net debt-$-22.17M-$-19.59M-$-4.23M-$-55.66M-$-84.06M
Cash flow statement
20252024202320222021
Net income-$-45.62M-$-36.18M-$-116.54M-$-87.97M-$-34.51M
Depreciation and amortization$310K$360K$370K$370K$200K
Stock-based compensation$10.5M$13.1M$6.54M$8.15M$7.9M
Change in working capital$7.65M$8.71M-$-4.92M$2.37M-$-150K
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$6.72M$7.75M-$-2.6M$2.08M$2.14M
Net cash provided by operating activities-$-62.34M-$-47.27M-$-39.53M-$-28.42M-$-28.91M
Investments in property, plant and equipment$0.00$0.00$0.00$0.00$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$10.8M-$-70.31M-$-45.29M$0.00$0.00
Common stock issued$53.6M$133.3M$33M$0.00-$-450K
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$53.8M$133.5M$33M$0.00-$-450K
Net change in cash$2.26M$15.9M-$-51.8M-$-28.42M-$-29.36M
Cash at end of period$22.8M$20.6M$4.61M$56.4M$84.8M
Operating cash flow-$-62.34M-$-47.27M-$-39.53M-$-28.42M-$-28.91M
Capital expenditure$0.00$0.00$0.00$0.00$0.00
Free cash flow-$-62.34M-$-47.27M-$-39.53M-$-28.42M-$-28.91M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Eledon Pharmaceuticals, Inc.

        Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating innovative treatments for individuals battling autoimmune disorders, amyotrophic lateral sclerosis (ALS), and those undergoing organ or cell transplantation. Their flagship therapeutic candidate, AT-1501, is a humanized monoclonal antibody engineered to specifically target CD40 Ligand, a crucial protein found on the surface of immune system T cells. This compound is currently undergoing Phase 2a clinical studies for ALS treatment and Phase 2 trials for islet cell transplantation, aiming to address type 1 diabetes. Previously known as Novus Therapeutics, Inc., the company adopted its current name, Eledon Pharmaceuticals, Inc., in January 2021. Its corporate headquarters are located in Irvine, California.

        CEO
        David-Alexandre C. Gros
        Employees
        33
        Beta
        0.96

        Explore

        Frequently asked questions

        What is the intrinsic value of Eledon Pharmaceuticals, Inc. (ELDN)?

        InvestorsCraft does not currently publish an intrinsic value for ELDN. How the IC value is calculated.

        Is ELDN undervalued?

        InvestorsCraft does not publish an undervaluation signal for ELDN at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.